Loading
A phase 1/2 trial of GIM122 in advanced solid tumours, run by Georgiamune Inc, now recruiting.
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT06028074 by Georgiamune Inc, with 111 participants planned, started 2023-12-12 and due to reach its primary completion in 2026-09. Interventions recorded: GIM122.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Georgiamune and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/